MeiraGTx (NASDAQ:MGTX) is a biotechnology company dedicated to developing cutting-edge gene therapy solutions for patients suffering from diseases of high unmet medical need. The primary focus of the company is on the development of treatments for eye diseases, salivary gland conditions, and neurodegenerative diseases. Throughout its operations, MeiraGTx aims to leverage its unique gene therapy platforms to create transformative treatments that can significantly improve the quality of life for patients worldwide. Their projects span from early discovery to late-stage development, emphasizing innovation, patient safety, and efficacy. By pursuing a deep understanding of genetic diseases, MeiraGTx's objective is to pioneer novel gene therapy solutions that address the root causes of these conditions, with the ultimate goal of delivering life-changing treatments to the patients and communities they serve.